FDA Reviewing Details of the Study | Approved Brentuximab

FDA Reviewing Details of the Study - Approved Brentuximab
Joseph M. Connors, MD shares FDA Reviewing Details of the Study | Approved Brentuximab at AACR 2018
756 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Hodgkin Lymphoma

Brentuximab Vedotin ABVD Hodgkin's Lymphoma Phase 3 Data
Brentuximab Vedotin ABVD Hodgkin's Lymphoma Phase 3 Data
34 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Sleep Apnea in Hodgkin's Lymphoma, Methotrexate and Neurocognitive Impairment
Sleep Apnea in Hodgkin's Lymphoma, Methotrexate and Neuro...
32 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Anita Kumar, MD @DrAnitaKumar @sloan_kettering #HodgkinLymphoma #Cancer #Research Brentuximab Vedotin Combined With Chemotherapy in Pts with Newly Diagnosed Early-Stage, Unfavorable-Risk ...
Anita Kumar, MD @DrAnitaKumar @sloan_kettering #HodgkinLy...
87 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Alex F. Herrera, MD @cityofhope #ASH20 # HodgkinLymphoma #cancer #research 472 Consolidation with Nivolumab and Brentuximab Vedotin
Alex F. Herrera, MD @cityofhope #ASH20 # HodgkinLymphoma ...
22 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research 5-Year Update of the ECHELON-1 Study
Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #Cla...
42 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Miles Prince, MD @MilesPrince4 @PeterMacCC #ASH20 #HodgkinsLymphoma #Cancer #Research The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study
Miles Prince, MD @MilesPrince4 @PeterMacCC #ASH20 #Hodgki...
24 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Anna Sureda, MD, Ph.D. @AnnaSureda5 @bloodcellbcn #ASH20 #classicalhodgkinlymphoma #cancer #research 5-Year Update of the ECHELON-1 Study
Anna Sureda, MD, Ph.D. @AnnaSureda5 @bloodcellbcn #ASH20 ...
47 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mehul Dalal, Ph.D. @TakedaOncology #ASH20 #hodgkinslymphoma #cancer #research Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma
Mehul Dalal, Ph.D. @TakedaOncology #ASH20 #hodgkinslympho...
18 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
John Kuruvilla, MD @pmcancercentre @UofT #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research Randomized, Phase 3, Keynote-204 Study
John Kuruvilla, MD @pmcancercentre @UofT #ASH20 #Classica...
27 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
William G. Wierda, MD, Ph.D. @wwierda @MDAndersonNews #ASH20 #Lymphoma #CAPTIVATE #Cancer #Research The first presentation of disease-free survival results from the CAPTIVATE study
William G. Wierda, MD, Ph.D. @wwierda @MDAndersonNews #AS...
37 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
John Kuruvilla, MD @pmcancercentre @UofT #classichodgkinlymphoma #cancer #research KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Adult Patients With Relapsed or Refractory cHL Afte...
John Kuruvilla, MD @pmcancercentre @UofT #classichodgkinl...
55 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Miguel Ferreira, MSc @globaldataplc #hodgkinslymphoma Hodgkin’s lymphoma market to suffer with Adcetris patent expiry but benefit from new competitive landscape, says GlobalData
Miguel Ferreira, MSc @globaldataplc #hodgkinslymphoma Hod...
227 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login